Novartis ‘committed’ to Sandoz

Novartis intends to retain and transform its Sandoz generics and biosimilars business, a group spokesperson has told Generics bulletin, in response to rumours in a Swiss newspaper that the firm was looking to spin off its Sandoz division in its entirety.